Noninvasive test for NASH, fibrosis in patients with psoriasis
25 August 2017

(HealthDay)—For patients with psoriasis receiving long-term methotrexate sodium therapy, a noninvasive test for nonalcoholic steatohepatitis (NASH) and hepatic fibrosis (NASH FibroSure) can be used to monitor development of methotrexate-induced hepatotoxic effects, with a significant correlation for cumulative methotrexate dose with higher score in women, but not men (P = 0.11). Except for one patient, all were managed without liver biopsy.

"In a single-institution cohort, these results suggest that NASH FibroSure may be used, especially among female patients, to help monitor for risk of worsening fibrosis during methotrexate therapy," the authors write.

More information: Abstract/Full Text

Copyright © 2017 HealthDay. All rights reserved.